Rosa Carla Patrícia Da Costa Pereira,Gusmão De Noronha Rita,Kiss Laszlo Erno,Soares Da Silva Patrício Manuel Vieira Araújo,Russo Domenico,Wahnon Jorge Bruno Reis,Maton William
申请号：
NZ70465113
公开号：
NZ704651A
申请日:
2013.07.24
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson’s disease, levodopa-induced dyskinesia, Huntington’s disease, Gilles de la Tourette’s syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer’s disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.
